Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases

Phase 1LBL-051Positive

AI Analysis

Summary

Leads Biolabs announced that partner Oblenio Bio has dosed the first patients in a Phase 1a trial of LBL-051, a tri-specific T-cell engager targeting CD19, BCMA, and CD3 for refractory autoimmune diseases. The first-in-human trial represents Oblenio's lead asset and aims to generate proof of concept.

Clinical Trial Data

Phase

Outcome Details

First patients dosed in Phase 1a trial

Importance:5/10

Sentiment:

0.60

Phase 1 trialT-cell engagerAutoimmune diseaseFirst-in-humanTri-specific

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 4, 2026 11:56 AM

Read Original